Cargando…

Prognostic Fifteen-Gene Signature for Early Stage Pancreatic Ductal Adenocarcinoma

The outcomes of patients treated with surgery for early stage pancreatic ductal adenocarcinoma (PDAC) are variable with median survival ranging from 6 months to more than 5 years. This challenge underscores an unmet need for developing personalized medicine strategies to refine the current treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Dung-Tsa, Davis-Yadley, Ashley H., Huang, Po-Yu, Husain, Kazim, Centeno, Barbara A., Permuth-Wey, Jennifer, Pimiento, Jose M., Malafa, Mokenge
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4527782/ https://www.ncbi.nlm.nih.gov/pubmed/26247463 http://dx.doi.org/10.1371/journal.pone.0133562

Ejemplares similares

A Phase I Safety, Pharmacokinetic, and Pharmacodynamic Presurgical Trial of Vitamin E δ-tocotrienol in Patients with Pancreatic Ductal Neoplasia
por: Springett, Gregory M., et al.
Publicado: (2015)

TGFβ1 overexpression is associated with improved survival and low tumor cell proliferation in patients with early-stage pancreatic ductal adenocarcinoma
por: Glazer, Evan S., et al.
Publicado: (2016)

Comparison of Radiomic Features in a Diverse Cohort of Patients With Pancreatic Ductal Adenocarcinomas
por: Permuth, Jennifer B., et al.
Publicado: (2021)

Vitamin E δ-Tocotrienol Induces p27(Kip1)-Dependent Cell-Cycle Arrest in Pancreatic Cancer Cells via an E2F-1-Dependent Mechanism
por: Hodul, Pamela J., et al.
Publicado: (2013)

δ-Tocotrienol, a natural form of vitamin E, inhibits pancreatic cancer stem-like cells and prevents pancreatic cancer metastasis
por: Husain, Kazim, et al.
Publicado: (2017)

Neutrophil to lymphocyte ratio, not platelet to lymphocyte or lymphocyte to monocyte ratio, is predictive of patient survival after resection of early-stage pancreatic ductal adenocarcinoma
por: Pointer, David T., et al.
Publicado: (2020)

Pancreatic Ductal Carcinoma Risk Associated With Hereditary Cancer-Risk Genes
por: Gardiner, Anna, et al.
Publicado: (2022)

Murine Pancreatic Adenocarcinoma Reduces Ikaros Expression and Disrupts T Cell Homeostasis
por: Nelson, Nadine, et al.
Publicado: (2015)

Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors
por: Hall, MacLean, et al.
Publicado: (2016)

Farnesyl dimethyl chromanol targets colon cancer stem cells and prevents colorectal cancer metastasis
por: Husain, Kazim, et al.
Publicado: (2021)

A Genome-Wide Investigation of MicroRNA Expression Identifies Biologically-Meaningful MicroRNAs That Distinguish between High-Risk and Low-Risk Intraductal Papillary Mucinous Neoplasms of the Pancreas
por: Permuth-Wey, Jennifer, et al.
Publicado: (2015)

Targeting the IκB Kinase Enhancer and Its Feedback Circuit in Pancreatic Cancer()
por: Challa, Sridevi, et al.
Publicado: (2020)

Case Report of Isolated Gastric Metastasis of Pancreatic Cancer From a Diagnostic Biopsy: Management of a Rare Oncologic Entity
por: Rothermel, Luke D., et al.
Publicado: (2020)

Combining radiomic features with a miRNA classifier may improve prediction of malignant pathology for pancreatic intraductal papillary mucinous neoplasms
por: Permuth, Jennifer B., et al.
Publicado: (2016)

Case report: Irreversible electroporation for locally advanced pancreatic cancer
por: Orcutt, Sonia, et al.
Publicado: (2017)

A pilot study to evaluate tissue- and plasma-based DNA driver mutations in a cohort of patients with pancreatic intraductal papillary mucinous neoplasms
por: Park, Margaret A, et al.
Publicado: (2022)

A Case Control Study of the Seroprevalence of Helicobacter pylori Proteins and Their Association with Pancreatic Cancer Risk
por: Permuth, Jennifer B., et al.
Publicado: (2021)

Pancreatic ductal adenocarcinoma staging
por: Al-Hawary, Mahmoud M., et al.
Publicado: (2013)

The limits of molecular signatures for pancreatic ductal adenocarcinoma subtyping
por: Lautizi, Manuela, et al.
Publicado: (2022)

The impact of age and comorbidity on localized pancreatic cancer outcomes: A US retrospective cohort analysis with implications for surgical centralization
por: Powers, Benjamin D., et al.
Publicado: (2023)

Ion Channel Signature in Healthy Pancreas and Pancreatic Ductal Adenocarcinoma
por: Schnipper, Julie, et al.
Publicado: (2020)

Minimally invasive image-guided therapy of primary and metastatic pancreatic cancer
por: Bibok, Andras, et al.
Publicado: (2021)

Hospital Surgical Volume Is Poorly Correlated With Delivery of Multimodal Treatment for Localized Pancreatic Cancer: A National Retrospective Cohort Study
por: Powers, Benjamin D., et al.
Publicado: (2022)

Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis
por: Mayerle, Julia, et al.
Publicado: (2018)

Vitamin E δ-tocotrienol sensitizes human pancreatic cancer cells to TRAIL-induced apoptosis through proteasome-mediated down-regulation of c-FLIP(s)
por: Francois, Rony A., et al.
Publicado: (2019)

Real time ex vivo chemosensitivity assay for pancreatic adenocarcinoma
por: Kim, Dae Won, et al.
Publicado: (2023)

Linc-ing Circulating Long Non-coding RNAs to the Diagnosis and Malignant Prediction of Intraductal Papillary Mucinous Neoplasms of the Pancreas
por: Permuth, Jennifer B., et al.
Publicado: (2017)

Circular RNA Signature Predicts Gemcitabine Resistance of Pancreatic Ductal Adenocarcinoma
por: Shao, Feng, et al.
Publicado: (2018)

Establishing and validating an ADCP-related prognostic signature in pancreatic ductal adenocarcinoma
por: Zhang, Deyu, et al.
Publicado: (2022)

Novel prognostic gene signature for pancreatic ductal adenocarcinoma based on hypoxia
por: Ren, Min, et al.
Publicado: (2023)

Desmoplastic stromal signatures predict patient outcomes in pancreatic ductal adenocarcinoma
por: Mascharak, Shamik, et al.
Publicado: (2023)

Correction: Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis
Publicado: (2018)

Multimodality Management of “Borderline Resectable” Pancreatic Neuroendocrine Tumors: Report of a Single-Institution Experience
por: Ambe, Chenwi M., et al.
Publicado: (2017)

Mimics of pancreatic ductal adenocarcinoma
por: Al-Hawary, Mahmoud M., et al.
Publicado: (2013)

Syndecans and Pancreatic Ductal Adenocarcinoma
por: Betriu, Nausika, et al.
Publicado: (2021)

Models of pancreatic ductal adenocarcinoma
por: Dennaoui, Rayane, et al.
Publicado: (2021)

A multi-gene signature predicts outcome in patients with pancreatic ductal adenocarcinoma
por: Haider, Syed, et al.
Publicado: (2014)

Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma
por: Tang, Rong, et al.
Publicado: (2021)

Identification of an Immune-Related Signature for Predicting Prognosis in Patients With Pancreatic Ductal Adenocarcinoma
por: Wang, Weijia, et al.
Publicado: (2021)

Development and Verification of the Hypoxia- and Immune-Associated Prognostic Signature for Pancreatic Ductal Adenocarcinoma
por: Chen, Dongjie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6863pa9an2e7t6m70dfps6klqs